‘Gamechanging’ cancer drug rejected for use on NHS

The Guardian, 11 April 2017
Author: Sarah Boseley
“A ‘gamechanging’ immunotherapy drug that can extend the life of patients with advanced head and neck cancer has been turned down for use in the NHS because of its high cost. Although nivolumab drug can give people with advanced head and neck cancers an extra three months of life, the National Institute for Health and Care Excellence (Nice) has rejected it. Nice believes nivolumab would cost between £66,000 to £75,000 per year of quality life.”
Find article here.